Bayer Zydus Pharma
Bayer Zydus Pharma is a joint venture between Bayer and Zydus Cadila in India. The focus of this business is on prescription products, especially for cardiology and women’s health care and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
The partnership combines Bayer’s expertise in successfully commercializing novel products, sophisticated administration and sales processes according to international standards with Zydus Cadila’s strong Indian marketing and sales expertise as well as excellent distribution network within the industry. Backed by strong research and development and a novel therapeutic approach, Bayer Zydus Pharma is focused on meeting the patients' healthcare needs in India.
Bayer Zydus Pharma concentrates its strengths in four business units: General Medicine, Women's Healthcare and Specialty Medicine
In the General Medicine Business Unit, Bayer Zydus Pharma markets products that are prescribed by both general practitioners and specialists. An extensive range of products for the control of high blood pressure, prevention of myocardial infarction and stroke, and for diabetes management provide doctors and patients with options not just for the treatment of acute conditions but also for prevention. The company also offers effective active ingredients to treat bacterial infections, such as respiratory and urinary tract infections.
The Women’s Healthcare Business Unit is a world leader in the field of women’s health and concentrates on three areas: contraception, menopause management and gynecological therapies. Bayer is the world market leader in the field of female hormonal contraception, especially in the area of oral contraceptives. The company uses its knowledge and experience to offer even better options for contraception, individualized therapies for menopausal complaints and therapies for gynecological disorders that, yet, cannot be treated sufficiently.
The Specialty Medicine Business Unit offers innovative treatment options with a view to producing a tangible improvement in the quality of life of people with serious chronic and life-threatening illnesses.